Integration of diverse data sources for prediction of adverse drug events.
The rapid evolution of large biological, pharmacological, and chemical databases has led to optimism that such data resources can be leveraged for prediction of drug action based on molecular descriptors of the drug. Challenges to realize this possibility include organization of each type of database in a manner that allows extraction of information across disparate data sources and the linkage of information across the biological, pharmacological, and chemical domains.
Office of Clinical Pharmacology, Office of Translational Science, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA. darrell.abernethy@fda.hhs.gov
D R
DR
Abernethy
J P F
JP
Bai
K
K
Burkhart
H-G
HG
Xie
P
P
Zhichkin
D000639:Amitriptyline / Q000009:adverse effects / Q000031:analogs & derivatives*; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects*; D006801:Humans; D020230:Serotonin Syndrome / Q000139:chemically induced*
D000929:Antidepressive Agents, Tricyclic; D000639:Amitriptyline; C004704:cyclobenzaprine